Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 5759542
SERIAL NO

08286748

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A fusion drug including an isolated portion of the A-chain of a urokinase-type plasminogen activator linked to a drug, wherein the A-chain portion binds stably to an outer membrane of a platelet. The T.sub.1/2 of the fusion drug in plasma is thereby increased to about 4 to 5 days, and the fusion drug is automatically targeted to forming thrombi and sites of vascular injury. The fusion drug can thus be used to treat cardiovascular diseases, e.g., as adjunctive therapy to inhibit reocclusions in a patient after thrombolytic therapy or angioplasty.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • NEW ENGLAND DEACONESS HOSPITAL CORPORATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gurewich, Victor Cambridge, MA 20 283

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation